Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Regulatory Filings 2021

May 27, 2021

29750_rns_2021-05-27_3171e61e-b0a6-42c3-b6d9-1983d20a64d0.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

SD 1 formsd2020.htm SD html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk Copyright 2021 Workiva Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form SD

S PECIALIZED D ISCLOSURE REPORT

Johnson & Johnson

(Exact Name of Registrant as Specified in Charter)

New Jersey 1-3215 22-1024240
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number)
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of Principal Executive Offices) (Zip Code)

Matthew Orlando, Corporate Secretary (732) 524-0400

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

ý Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2020.

Section 1 - Conflict Minerals Disclosure

Item 1.01 Conflict Minerals Disclosure and Report

Conflict Minerals Disclosure

A copy of the Company’s Conflict Minerals Report filed for the calendar year ended December 31, 2020 is publicly available at http://www.investor.jnj.com/governance/sec-filings.cfm . The content of any website referred to in this Form SD, including any exhibit hereto, is included for general information only and is not incorporated by reference in this Form SD.

Item 1.02 Exhibit

The Company’s Conflict Minerals Report for the calendar year ended December 31, 2020 is filed as Exhibit 1.01 to this Form SD.

Section 2 - Exhibits

Item 2.01 Exhibits

Exhibit No. Description

Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Johnson & Johnson

By: /s/ Joseph J. Wolk
Joseph J. Wolk
Executive Vice President, Chief Financial Officer